



THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

8 May 2024

Genflow Biosciences Plc

Restoration of Listing

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) (“Genflow” or “the Company”), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce that, following publication of the audited financial statements for the year ended 31 December 2023 (**FY23 Results**) on 7 May 2024, and having completed the upload of the FY23 Results to the Financial Conduct Authority's National Storage Mechanism at www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism, it has been advised by the FCA that the temporary suspension of listing of the Company's ordinary shares on the Official List of the Financial Conduct Authority is expected to be lifted later today, 8 May 2024, and that the listing on the Main Market of the London Stock Exchange, of the ordinary shares, will be restored.

Contacts

Genflow Biosciences

Dr Eric Leire, CEO

+32-477-495-881

Harbor Access

Jonathan Paterson, Investor Relations

+1 475 477 9401

Jonathan.Paterson@Harbor-access.com

Joint Corporate Brokers

Clear Capital Markets

Bob Roberts, +44 203 869 6080

Capital Plus Partners Ltd

Dominic Berger, +44 203 821 6167

Keith Swann, +44 0203 821 6169

Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and



social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating NASH; now called MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.

Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.